Gilead Announces Pivotal Phase 2 Data for Idelalisib in Refractory Indolent ... Business Wire (press release) Study 101-09 is a Phase 2, open-label, single-arm efficacy and safety study of idelalisib in patients with previously treated iNHL that is refractory both to rituximab and to alkylating-agent-containing chemotherapy (refractory defined as no response ... |
